Trastuzumab (T) plus oral vinorelbine (OV) in patients with advanced breast cancer (ABC) overexpressing Her2/neu

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [41] Trastuzumab (Herceptin®):: Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
    Ditsch, Nina
    Rueckert, Sandra
    Kuemper, Carolin
    Lenhard, Miriam
    Kahlert, Steffen
    Bauerfeind, Ingo
    Friese, Klaus
    Untch, Michael
    BREAST CARE, 2006, 1 (02) : 78 - 84
  • [42] Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
    Faltus, T
    Yuan, JP
    Zimmer, B
    Krämer, A
    Loibl, S
    Kaufmann, M
    Strebhardt, K
    NEOPLASIA, 2004, 6 (06): : 786 - 795
  • [43] METRONOMIC ORAL VINORELBINE (OV) IN ADVANCED BREAST CANCER PATIENTS (ABC): PRELIMINARY RESULTS OF A CLINICAL AND BIOMARKER PHASE II STUDY
    Munzone, E.
    Esposito, A.
    Cullura, D.
    Bertolini, F.
    Sandri, M. T.
    Petralia, G.
    Adamoli, L.
    Radice, D.
    Marenghi, C.
    Magni, E.
    Goldhirsch, A.
    Nole, F.
    ANNALS OF ONCOLOGY, 2009, 20
  • [44] Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
    Kerklaan, Bojana Milojkovic
    Dieras, Veronique
    Le Tourneau, Christophe
    Mergui-Roelvink, Marja
    Huitema, Alwin D. R.
    Rosing, Hilde
    Beijnen, Jos H.
    Marreaud, Sandrine
    Govaerts, Anne-Sophie
    Piccart-Gebhart, Martine J.
    Schellens, Jan H. M.
    Awada, Ahmad
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 53 - 62
  • [45] Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
    Bojana Milojkovic Kerklaan
    Veronique Diéras
    Christophe Le Tourneau
    Marja Mergui-Roelvink
    Alwin D. R. Huitema
    Hilde Rosing
    Jos H. Beijnen
    Sandrine Marreaud
    Anne-Sophie Govaerts
    Martine J. Piccart-Gebhart
    Jan H. M. Schellens
    Ahmad Awada
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 53 - 62
  • [46] Proteomic analysis of breast cancer cell lines overexpressing the Her2/neu oncogene
    Fragkos-Livanios, L.
    Gartaganis, V.
    Samiotaki, M.
    Baxevanis, C. N.
    Panayotou, G.
    FEBS JOURNAL, 2008, 275 : 332 - 332
  • [47] Her2/neu status in locally advanced breast cancer.
    Doran, CM
    Cameron, DA
    Watters, AD
    Leonard, RCF
    Bartlett, JMS
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 278 - 278
  • [48] Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
    Mittendorf, Elizabeth A.
    Storrer, Catherine E.
    Shriver, Craig D.
    Ponniah, Sathibalan
    Peoples, George E.
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (08) : 1085 - 1098
  • [49] Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer
    Elizabeth A. Mittendorf
    Catherine E. Storrer
    Craig D. Shriver
    Sathibalan Ponniah
    George E. Peoples
    Annals of Surgical Oncology, 2006, 13 : 1085 - 1098
  • [50] Trastuzumab - A review of its use in the treatment of metastatic breast cancer overexpressing HER2
    McKeage, K
    Perry, CM
    DRUGS, 2002, 62 (01) : 209 - 243
12345